In simple words: This lab test analyzes a tumor sample to look for genetic changes (mutations) in the DNA and RNA.It checks for several types of changes and measures how many mutations are present. This helps doctors determine the best cancer treatment plan.

This CPT code encompasses a comprehensive genomic sequence analysis panel designed to evaluate a solid organ neoplasm specimen.The analysis includes DNA and/or RNA sequencing to identify sequence variants, copy number variants, and rearrangements.Furthermore, it assesses microsatellite instability (MSI) and tumor mutation burden (TMB), crucial factors impacting diagnosis and treatment strategies. This panel utilizes advanced techniques such as next-generation sequencing (NGS).

Example 1: A patient with lung cancer undergoes a biopsy. The tissue is sent to the lab for 81459 testing to identify specific genetic mutations that could inform targeted therapy selection., A patient with colon cancer has surgery. A section of the tumor is sent for 81459 testing to assess tumor mutational burden (TMB) to help determine eligibility for immunotherapy., A patient with a suspected metastatic melanoma undergoes a sentinel lymph node biopsy. The tissue is analyzed using 81459 to detect specific genetic alterations which might indicate sensitivity to specific targeted therapy.

* Patient demographics and medical record number.* Detailed pathology report with specimen identification and collection date.* Oncologist's order indicating the need for comprehensive genomic profiling.* Complete lab reports including all sequencing data, variants identified, MSI status and TMB score.* Clinician's interpretation of the test results and subsequent treatment plan.

** This code is part of a family of codes designed to provide a comprehensive approach to genomic sequencing for solid organ neoplasms.The selection of the appropriate code within this family depends on the specific analyses performed and whether cell-free DNA is used.